Correlation Between Kinnate Biopharma and Beam Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kinnate Biopharma and Beam Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kinnate Biopharma and Beam Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kinnate Biopharma and Beam Therapeutics, you can compare the effects of market volatilities on Kinnate Biopharma and Beam Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kinnate Biopharma with a short position of Beam Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kinnate Biopharma and Beam Therapeutics.

Diversification Opportunities for Kinnate Biopharma and Beam Therapeutics

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between Kinnate and Beam is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Kinnate Biopharma and Beam Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Beam Therapeutics and Kinnate Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kinnate Biopharma are associated (or correlated) with Beam Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Beam Therapeutics has no effect on the direction of Kinnate Biopharma i.e., Kinnate Biopharma and Beam Therapeutics go up and down completely randomly.

Pair Corralation between Kinnate Biopharma and Beam Therapeutics

If you would invest  2,720  in Beam Therapeutics on September 28, 2024 and sell it today you would earn a total of  150.00  from holding Beam Therapeutics or generate 5.51% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy5.0%
ValuesDaily Returns

Kinnate Biopharma  vs.  Beam Therapeutics

 Performance 
       Timeline  
Kinnate Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kinnate Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Kinnate Biopharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.
Beam Therapeutics 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Beam Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Beam Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Kinnate Biopharma and Beam Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kinnate Biopharma and Beam Therapeutics

The main advantage of trading using opposite Kinnate Biopharma and Beam Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kinnate Biopharma position performs unexpectedly, Beam Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Beam Therapeutics will offset losses from the drop in Beam Therapeutics' long position.
The idea behind Kinnate Biopharma and Beam Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data